Nasdaq ikna.

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...May 15, 2023 · Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ... BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Risk Analysis Highly volatile share price over the past 3 months Earnings are forecast to decline by an average of 10.5% per year for the next 3 years Does not have a …

(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena Oncology. stock was originally listed at a price of $28.30 in Mar 29, 2021.

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Dec 17, 2021 · He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ... Webull offers Ikena Oncology (IKNA) historical stock prices, in-depth market analysis, NASDAQ: IKNA real-time stock quote data, in-depth charts.BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient …

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry ...BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...Dec 11, 2021 · About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ... IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... BeyondSpring Inc. (NASDAQ: BYSI) was among the biggest biopharma gainers of the week, with the stock reacting to a positive late-stage readout for its lung cancer treatment combo. The stock ended ...Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ... BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%.

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Ikena Oncology, Inc. is traded on the NASDAQ under the ticker symbol "IKNA". What is Ikena Oncology's primary industry? Company operates in the Healthcare ...

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Formula One Group (NASDAQ:FWONA) has seen a decrease in hedge fund sentiment lately. Formula One Group (NASDAQ: FWONA ) was in 19 hedge funds' portfolios at the end of the first quarter of 2021 ...Ikena Oncology, Inc. (NASDAQ:IKNA) Achilles Therapeutics plc (NASDAQ:ACHL) Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates . Photo by Thought Catalog on Unsplash.

Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ...

Nov 10, 2021 · As of September 30, 2021, the Company had cash and cash equivalents totaling $245.9 million, which will fund operations through 2023. Net cash used in operations was $18.0 million for the third ...

Franchiser Inter IKEA said sales of products and services at all IKEA stores and online totalled 41.9 billion euros ($48.7 billion) - up 6% from the previous fiscal year and up 1% from pre ...Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Ikena Oncology (NASDAQ:IKNA) with a Buy recommendation. Analyst Price Forecast Suggests 210.16% Upside. As of May 11 ...Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...Dec 1, 2023 · Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million. BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nov 30, 2023 · (NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M. Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. Atreca, Inc. (NASDAQ:BCEL) announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types, showing the investigational asset ...Ikena Oncology, Inc. Common Stock (IKNA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...

Ikena Oncology Inc (NASDAQ:IKNA) 1.51 Delayed Data As of Dec 01 +0.06 / +4.14% Today’s Change 1.02 Today ||| 52-Week Range 7.64 -43.23% Year-to-Date Quote Profile …Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Ikena Oncology (NASDAQ:IKNA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and …About KludeIn I Acquisition Corp. 1096 KEELER AVENUE, BERKELEY, California, 94708, United States +1 650 246-9907. KludeIn I Acquisition Corp is a blank check company.Instagram:https://instagram. dollar7 reit with 16.5 dividendapparel stockschico's fas stockgeorge clooney tequila company Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d. monthly dividend etf listringcentral nyse BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million. investing in brics Investing.com - Ikena Oncology (NASDAQ: IKNA) reported third quarter EPS of $-0.40, $0.03 better than the analyst estimate of $-0.43. Revenue for the quarter came in at $1.19M versus the... Investing.com; Nov 10, 2023 04:11; H.C. Wainwright maintains Ikena Oncology at 'buy' with a price target of $11.00 .BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...